NASDAQ:NTRA - Natera Stock Price, Forecast & News

Natera trades on the NASDAQ under the ticker symbol "NTRA."

Natera Inc (NASDAQ:NTRA) released its quarterly earnings data on Wednesday, November, 6th. The medical research company reported ($0.33) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.53) by $0.20. The medical research company earned $77.90 million during the quarter, compared to the consensus estimate of $73.97 million. Natera had a negative return on equity of 252.79% and a negative net margin of 42.45%. The firm's revenue was up 19.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.49) earnings per share. View Natera's Earnings History.

Natera is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Natera.

5 equities research analysts have issued 12-month price objectives for Natera's stock. Their forecasts range from $32.00 to $49.00. On average, they expect Natera's share price to reach $42.40 in the next twelve months. This suggests a possible upside of 18.7% from the stock's current price. View Analyst Price Targets for Natera.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Natera.

Media coverage about NTRA stock has trended extremely negative on Monday, InfoTrie reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Natera earned a news impact score of -4.5 on InfoTrie's scale. They also gave news articles about the medical research company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Natera.

Natera saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 3,640,000 shares, an increase of 30.5% from the December 31st total of 2,790,000 shares. Based on an average daily volume of 758,700 shares, the short-interest ratio is presently 4.8 days. Approximately 5.4% of the shares of the stock are short sold. View Natera's Current Options Chain.

Some companies that are related to Natera include Guardant Health (GH), ELEKTA AB/ADR (EKTAY), InVitae (NVTA), Veracyte (VCYT), RadNet (RDNT), CareDx (CDNA), Castle Biosciences (CSTL), Personalis (PSNL), Centogene (CNTG), Fulgent Genetics (FLGT), DermTech (DMTK), Enzo Biochem (ENZ), Celcuity (CELC), Psychemedics (PMD) and Miragen Therapeutics (MGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Athabasca Oil (ATH), Chipotle Mexican Grill (CMG), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN).

(NTRA) raised $101 million in an initial public offering (IPO) on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Natera's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Columbus Circle Investors (0.70%), HWG Holdings LP (0.04%), Strs Ohio (0.04%), Zurcher Kantonalbank Zurich Cantonalbank (0.00%) and Exchange Traded Concepts LLC (0.00%). Company insiders that own Natera stock include Claremont Creek Partners Fund, John Steuart, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren and Steven Leonard Chapman. View Institutional Ownership Trends for Natera.

NTRA stock was bought by a variety of institutional investors in the last quarter, including Columbus Circle Investors, HWG Holdings LP, Exchange Traded Concepts LLC, Strs Ohio and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Natera.

Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NTRA stock can currently be purchased for approximately $35.71.

Natera has a market capitalization of $2.77 billion and generates $257.65 million in revenue each year. The medical research company earns $-128,150,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. Natera employs 975 workers across the globe.View Additional Information About Natera.

The official website for Natera is http://www.natera.com/.

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at 650-249-9090 or via email at [email protected]